Matches in SemOpenAlex for { <https://semopenalex.org/work/W4381429577> ?p ?o ?g. }
- W4381429577 abstract "TLR Agonists have promising activity in preclinical models of viral infection and cancer. However, clinical use is only in topical application. Systemic uses of TLR-ligands such as Resiquimod, have failed due to adverse effects that limited dose and thus, efficacy. This issue could be related to pharmacokinetic properties that include fast elimination leading to low AUC with simultaneously high c max at relevant doses. The high c max is associated with a sharp, poorly tolerated cytokine pulse, suggesting that a compound with a higher AUC/c max -ratio could provide a more sustained and tolerable immune activation. Our approach was to design TLR7/8-agonist Imidazoquinolines intended to partition to endosomes via acid trapping using a macrolide-carrier. This can potentially extend pharmacokinetics and simultaneously direct the compounds to the target compartment. The compounds have hTLR7/8-agonist activity (EC50 of the most active compound in cellular assays: 75-120 nM hTLR7, 2.8-3.1 µM hTLR8) and maximal hTLR7 activation between 40 and 80% of Resiquimod. The lead candidates induce secretion of IFNα from human Leukocytes in the same range as Resiquimod but induce at least 10-fold less TNFα in this system, consistent with a higher specificity for human TLR7. This pattern was reproduced in vivo in a murine system, where small molecules are thought not to activate TLR8. We found that Imidazoquinolines conjugated to a macrolide or, substances carrying an unlinked terminal secondary amine, had longer exposure compared with Resiquimod. The kinetics of pro-inflammatory cytokine release for these substances in vivo were slower and more extended (for comparable AUCs, approximately half-maximal plasma concentrations). Maximal IFNα plasma levels were reached 4 h post application. Resiquimod-treated groups had by then returned to baseline from a peak at 1 h. We propose that the characteristic cytokine profile is likely a consequence of altered pharmacokinetics and, potentially, enhanced endosomal tropism of the novel substances. In particular, our substances are designed to partition to cellular compartments where the target receptor and a distinct combination of signaling molecules relevant to IFNα-release are located. These properties could address the tolerability issues of TLR7/8 ligands and provide insight into approaches to fine-tune the outcomes of TLR7/8 activation by small molecules." @default.
- W4381429577 created "2023-06-21" @default.
- W4381429577 creator A5007013436 @default.
- W4381429577 creator A5007572029 @default.
- W4381429577 creator A5008427939 @default.
- W4381429577 creator A5032295097 @default.
- W4381429577 creator A5035209135 @default.
- W4381429577 creator A5040071108 @default.
- W4381429577 creator A5040860797 @default.
- W4381429577 creator A5043635294 @default.
- W4381429577 creator A5070818577 @default.
- W4381429577 creator A5073497644 @default.
- W4381429577 creator A5080463673 @default.
- W4381429577 date "2023-06-20" @default.
- W4381429577 modified "2023-09-26" @default.
- W4381429577 title "Imidazoquinolines with improved pharmacokinetic properties induce a high IFNα to TNFα ratio in vitro and in vivo" @default.
- W4381429577 cites W1542775986 @default.
- W4381429577 cites W1598108315 @default.
- W4381429577 cites W1738782024 @default.
- W4381429577 cites W1951507118 @default.
- W4381429577 cites W1972776583 @default.
- W4381429577 cites W1991236592 @default.
- W4381429577 cites W1997977259 @default.
- W4381429577 cites W2001747259 @default.
- W4381429577 cites W2015312749 @default.
- W4381429577 cites W2015649564 @default.
- W4381429577 cites W2027545702 @default.
- W4381429577 cites W2033023829 @default.
- W4381429577 cites W2036807187 @default.
- W4381429577 cites W2036970411 @default.
- W4381429577 cites W2037827983 @default.
- W4381429577 cites W2040706148 @default.
- W4381429577 cites W2052521175 @default.
- W4381429577 cites W2054680036 @default.
- W4381429577 cites W2055679693 @default.
- W4381429577 cites W2060351820 @default.
- W4381429577 cites W2062267695 @default.
- W4381429577 cites W2062392673 @default.
- W4381429577 cites W2066725789 @default.
- W4381429577 cites W2067678108 @default.
- W4381429577 cites W2069975147 @default.
- W4381429577 cites W2080877766 @default.
- W4381429577 cites W2082669319 @default.
- W4381429577 cites W2084497436 @default.
- W4381429577 cites W2096099936 @default.
- W4381429577 cites W2096213695 @default.
- W4381429577 cites W2111922856 @default.
- W4381429577 cites W2122855649 @default.
- W4381429577 cites W2123662098 @default.
- W4381429577 cites W2134119588 @default.
- W4381429577 cites W2155860623 @default.
- W4381429577 cites W2156369327 @default.
- W4381429577 cites W2160775559 @default.
- W4381429577 cites W2345399978 @default.
- W4381429577 cites W2416115344 @default.
- W4381429577 cites W2530273804 @default.
- W4381429577 cites W2618081269 @default.
- W4381429577 cites W2757983152 @default.
- W4381429577 cites W2761099324 @default.
- W4381429577 cites W2770411652 @default.
- W4381429577 cites W2904734349 @default.
- W4381429577 cites W2912593436 @default.
- W4381429577 cites W2915025135 @default.
- W4381429577 cites W2931761017 @default.
- W4381429577 cites W2946496608 @default.
- W4381429577 cites W2980572764 @default.
- W4381429577 cites W2982401067 @default.
- W4381429577 cites W2993185426 @default.
- W4381429577 cites W3011884918 @default.
- W4381429577 cites W3012283572 @default.
- W4381429577 cites W3028523516 @default.
- W4381429577 cites W3134655285 @default.
- W4381429577 cites W3152003004 @default.
- W4381429577 cites W3178465786 @default.
- W4381429577 cites W3181109913 @default.
- W4381429577 cites W3206270822 @default.
- W4381429577 cites W4212909415 @default.
- W4381429577 cites W4239078387 @default.
- W4381429577 cites W4249383371 @default.
- W4381429577 cites W4282045748 @default.
- W4381429577 cites W4303628934 @default.
- W4381429577 cites W4361866506 @default.
- W4381429577 cites W2098751820 @default.
- W4381429577 doi "https://doi.org/10.3389/fimmu.2023.1168252" @default.
- W4381429577 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37409123" @default.
- W4381429577 hasPublicationYear "2023" @default.
- W4381429577 type Work @default.
- W4381429577 citedByCount "0" @default.
- W4381429577 crossrefType "journal-article" @default.
- W4381429577 hasAuthorship W4381429577A5007013436 @default.
- W4381429577 hasAuthorship W4381429577A5007572029 @default.
- W4381429577 hasAuthorship W4381429577A5008427939 @default.
- W4381429577 hasAuthorship W4381429577A5032295097 @default.
- W4381429577 hasAuthorship W4381429577A5035209135 @default.
- W4381429577 hasAuthorship W4381429577A5040071108 @default.
- W4381429577 hasAuthorship W4381429577A5040860797 @default.
- W4381429577 hasAuthorship W4381429577A5043635294 @default.
- W4381429577 hasAuthorship W4381429577A5070818577 @default.
- W4381429577 hasAuthorship W4381429577A5073497644 @default.
- W4381429577 hasAuthorship W4381429577A5080463673 @default.